Not a good buy right now: price action is in a clear downtrend with bearish momentum (MACD worsening) and weak trend structure (SMA200 > SMA20 > SMA5).
Near-term risk is elevated into the upcoming Q4 2025 earnings (after hours 2026-02-26), with recent quarters showing sharp YoY deterioration.
Wall Street stance is broadly negative (Sell/Underperform and multiple target cuts), so dips can keep getting sold despite “oversold” readings.
For an impatient buyer, the setup lacks a catalyst + confirmation; the higher-probability move is further chop/down toward lower support rather than a clean rebound.
Momentum: MACD histogram at -0.228 and negatively expanding = downside momentum is strengthening.
RSI: RSI_6 = 27.205, which is oversold (can bounce), but oversold alone is not a buy signal in a strong downtrend.
Levels:
Immediate support: S1 ~20.171 (price 20.05 is already slightly below/at this zone); next support S2 ~18.931.
Overhead resistance/pivot: Pivot ~22.178; then R1 ~24.186.
Pattern-based forward odds (similar candlesticks): modestly positive next day (+1.64% with 40% chance) but flat-to-negative beyond that (next month -0.37%), consistent with weak follow-through risk.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/Sentiment:
Open interest put/call ratio 0.33 = call-heavy open interest (mildly bullish positioning).
Volume put/call ratio 0.88 = slightly more call volume than puts (not extreme).
Volatility: 30D IV 84.32 vs historical vol 39.52 = options are pricing large moves (event risk likely tied to upcoming earnings).
IV context: IV percentile 62.15 (elevated vs its own history); near-term uncertainty remains high.
Liquidity note: Today’s option volume is low (32 total contracts), so sentiment signals from volume are not very robust.
Technical Summary
Sell
8
Buy
5
Positive Catalysts
Upcoming earnings event (Q4 2025 on 2026-02-26 after hours) can act as a reset/catalyst if guidance surprises positively.
Oversold RSI can produce short, sharp technical bounces—especially if broader market stabilizes.
Neutral/Negative Catalysts
Earnings risk: market is pricing high movement (very elevated IV), and the last reported quarter showed significant deterioration—skewing risk to downside.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $83.26M, down -15.58% YoY (contraction).
Net income: $1.533M, down -91.11% YoY (profitability compression).
EPS: $0.05, down -90.20% YoY.
Gross margin: 78.65%, down -9.16% YoY.
Takeaway: growth and profitability trends were decisively negative in the latest quarter, which aligns with the stock’s bearish technical setup heading into the next earnings.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: ratings skew bearish with price targets cut after Q3 results.
Evercore ISI (2025-11-13): PT cut to $32 from $38; kept In Line; noted results were a “mixed bag” and transformation will take time.
Goldman Sachs (2025-11-13): PT cut to $23 from $26; maintained Sell; transition remains a work in progress.
BofA (2025-11-13): PT cut to $22 from $24; maintained Underperform; reduced 2026/2027 revenue and EBITDA forecasts.
Wall Street pros vs cons summary:
Pros: potential longer-term upside if platform transition succeeds; at least one neutral rating with higher PT.
Cons: multiple bearish ratings, downward estimate revisions, and repeated emphasis on execution/transformation risk—near-term narrative remains negative.
Wall Street analysts forecast IBTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBTA is 28 USD with a low forecast of 22 USD and a high forecast of 33 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast IBTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBTA is 28 USD with a low forecast of 22 USD and a high forecast of 33 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
2 Sell
Hold
Current: 19.250
Low
22
Averages
28
High
33
Current: 19.250
Low
22
Averages
28
High
33
Evercore ISI
In Line
downgrade
$38 -> $32
AI Analysis
2025-11-13
Reason
Evercore ISI
Price Target
$38 -> $32
AI Analysis
2025-11-13
downgrade
In Line
Reason
Evercore ISI lowered the firm's price target on Ibotta to $32 from $38 and keeps an In Line rating on the shares following Q3 results that the firm calls "a mixed bag." Revenue and EBITDA estimates for 2026 have been cut by 11% and 16%, respectively, reflecting ongoing concerns, notes the analyst, who adds that "transformation takes time."
Goldman Sachs
Sell
downgrade
$26 -> $23
2025-11-13
Reason
Goldman Sachs
Price Target
$26 -> $23
2025-11-13
downgrade
Sell
Reason
Goldman Sachs lowered the firm's price target on Ibotta to $23 from $26 and keeps a Sell rating on the shares. The "LiveLift" platform transition remains a work in progress, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IBTA
